JP2022531388A5 - - Google Patents

Info

Publication number
JP2022531388A5
JP2022531388A5 JP2021564995A JP2021564995A JP2022531388A5 JP 2022531388 A5 JP2022531388 A5 JP 2022531388A5 JP 2021564995 A JP2021564995 A JP 2021564995A JP 2021564995 A JP2021564995 A JP 2021564995A JP 2022531388 A5 JP2022531388 A5 JP 2022531388A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
group
phenyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021564995A
Other languages
English (en)
Japanese (ja)
Other versions
JP7667573B2 (ja
JP2022531388A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/031046 external-priority patent/WO2020227101A1/en
Publication of JP2022531388A publication Critical patent/JP2022531388A/ja
Publication of JP2022531388A5 publication Critical patent/JP2022531388A5/ja
Priority to JP2025062493A priority Critical patent/JP2025102975A/ja
Application granted granted Critical
Publication of JP7667573B2 publication Critical patent/JP7667573B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021564995A 2019-05-03 2020-05-01 Kcnt1阻害剤および使用する方法 Active JP7667573B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025062493A JP2025102975A (ja) 2019-05-03 2025-04-04 Kcnt1阻害剤および使用する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962842849P 2019-05-03 2019-05-03
US62/842,849 2019-05-03
US202062982864P 2020-02-28 2020-02-28
US62/982,864 2020-02-28
PCT/US2020/031046 WO2020227101A1 (en) 2019-05-03 2020-05-01 Kcnt1 inhibitors and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025062493A Division JP2025102975A (ja) 2019-05-03 2025-04-04 Kcnt1阻害剤および使用する方法

Publications (3)

Publication Number Publication Date
JP2022531388A JP2022531388A (ja) 2022-07-06
JP2022531388A5 true JP2022531388A5 (cg-RX-API-DMAC10.html) 2023-05-11
JP7667573B2 JP7667573B2 (ja) 2025-04-23

Family

ID=73051241

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021564995A Active JP7667573B2 (ja) 2019-05-03 2020-05-01 Kcnt1阻害剤および使用する方法
JP2025062493A Pending JP2025102975A (ja) 2019-05-03 2025-04-04 Kcnt1阻害剤および使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025062493A Pending JP2025102975A (ja) 2019-05-03 2025-04-04 Kcnt1阻害剤および使用する方法

Country Status (17)

Country Link
US (1) US20220259193A1 (cg-RX-API-DMAC10.html)
EP (1) EP3962481A4 (cg-RX-API-DMAC10.html)
JP (2) JP7667573B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220016086A (cg-RX-API-DMAC10.html)
CN (2) CN120817941A (cg-RX-API-DMAC10.html)
AU (1) AU2020267356B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021022067A2 (cg-RX-API-DMAC10.html)
CA (1) CA3139063A1 (cg-RX-API-DMAC10.html)
CL (2) CL2021002877A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021016471A2 (cg-RX-API-DMAC10.html)
EC (1) ECSP21087884A (cg-RX-API-DMAC10.html)
IL (1) IL287768A (cg-RX-API-DMAC10.html)
MX (1) MX2021013421A (cg-RX-API-DMAC10.html)
PE (1) PE20220016A1 (cg-RX-API-DMAC10.html)
SA (1) SA521430751B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202112158YA (cg-RX-API-DMAC10.html)
WO (1) WO2020227101A1 (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12590083B2 (en) 2019-01-25 2026-03-31 University Of Virginia Patent Foundation Inhibitors of spinster homolog 2 (SPNS2) for use in therapy
EP4446314A3 (en) * 2019-05-03 2025-03-12 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
EP4110317B1 (en) * 2020-02-28 2025-11-19 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2022056042A1 (en) * 2020-09-09 2022-03-17 University Of Virginia Patent Foundation Inhibitors of spinster homolog 2 (spns2) for use in therapy
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
TW202227424A (zh) * 2020-11-27 2022-07-16 大陸商瑞石生物醫藥有限公司 芳基或雜芳基取代5員芳雜環化合物及其用途
US20240043415A1 (en) * 2020-12-22 2024-02-08 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
EP4329735B1 (en) * 2021-04-29 2026-02-25 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2022231872A1 (en) * 2021-04-29 2022-11-03 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2023211850A1 (en) * 2022-04-25 2023-11-02 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use
EP4536644A4 (en) * 2022-06-08 2026-05-20 Praxis Prec Medicines Inc KCNT1 INHIBITORS COMPRISING AN ISOXAZOLE OR OXADIAZOLE NUCLEUS AND METHODS OF USE
CN116813505B (zh) * 2023-06-29 2025-09-02 爱斯特(成都)生物制药股份有限公司 一种制备o-甲基-n-苄氧羰基-l-高丝氨酸的方法
CN122555695A (zh) * 2023-11-29 2026-08-11 爱克堤欧生物科学股份有限公司 可用作kcnt1抑制剂的杂环化合物
WO2026082925A1 (en) 2024-10-18 2026-04-23 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of their use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
TW200301698A (en) * 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
JP2005060255A (ja) * 2003-08-20 2005-03-10 Nippon Nohyaku Co Ltd カルボキサミド類及びこれを有効成分とする有害生物防除剤
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
BRPI0713187A2 (pt) * 2006-07-20 2012-10-16 Mehmet Kahraman método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica
CA2903979A1 (en) * 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
CA2962922C (en) 2014-09-29 2021-10-26 The Scripps Research Institute Sphingosine-1-phosphate receptor modulators for treatment of cardiopulmonary disorders
EP3275440B1 (en) * 2015-03-25 2022-05-04 National Center for Geriatrics and Gerontology Novel oxadiazole derivative and pharmaceutical containing same
JPWO2017170826A1 (ja) * 2016-03-30 2019-02-14 味の素株式会社 グルカゴン様ペプチド−1受容体作用増強活性を有する化合物
WO2018187480A1 (en) * 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
EP4110317B1 (en) * 2020-02-28 2025-11-19 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
KR20230005168A (ko) * 2020-03-23 2023-01-09 프락시스 프리시젼 메디신즈, 인크. Kcnt1 억제제 및 사용 방법
CN116075297A (zh) * 2020-07-06 2023-05-05 普拉西斯精密医药公司 Kcnt1抑制剂和使用方法
US11773088B2 (en) * 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
US20240043415A1 (en) * 2020-12-22 2024-02-08 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
EP4329735B1 (en) * 2021-04-29 2026-02-25 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use

Similar Documents

Publication Publication Date Title
JP2022530989A5 (cg-RX-API-DMAC10.html)
JP2023518838A5 (cg-RX-API-DMAC10.html)
EP0943616B1 (en) Substituted imidazole derivatives and their use as cytokine inhibitors
CN112638877B (zh) 用于治疗rna病毒感染的苯基/吡啶基-n-苯基/吡啶基衍生物
JP4648630B2 (ja) アミノインダゾール誘導体、その製造方法、医薬としての該方法の中間体の使用および該誘導体を含む医薬組成物
JP2010513519A5 (cg-RX-API-DMAC10.html)
KR100806978B1 (ko) 1,5-이치환된-3,4-디히드로-1h-피리미도[4,5-d]피리미딘-2-온 화합물 및 csbp/p38 키나제 매개된 질환의치료시 이들의 용도
JP2005514398A5 (cg-RX-API-DMAC10.html)
JP4157325B2 (ja) Cox−2のインヒビターとして有用なジアリールピリジンの製造方法
JP2021501151A5 (cg-RX-API-DMAC10.html)
JP6816106B2 (ja) 6−ピリジル−1,3,5−トリアジン−2,4−ジオール及び6−ピリジル−1,3,5−トリアジン−2,4−ジアミンを調製する方法
JP2023532985A5 (cg-RX-API-DMAC10.html)
JP2015522036A5 (cg-RX-API-DMAC10.html)
JP2017537949A5 (cg-RX-API-DMAC10.html)
UA71535C2 (en) Corticotropine-releasing antagonists factor, methods for the preparation thereof, pharmaceuitical composition and a method for the treatment
RU2010130559A (ru) Гербицидные пиридазиновые производные
JP2006506462A5 (cg-RX-API-DMAC10.html)
JP2011500758A5 (cg-RX-API-DMAC10.html)
EA023766B1 (ru) Триазолопиридины
JP2023515576A5 (cg-RX-API-DMAC10.html)
JP2015516429A5 (cg-RX-API-DMAC10.html)
CN113831320B (zh) 一种稠和吡唑类化合物的制备方法
JP2025066800A (ja) Bax阻害剤およびその使用
JPWO2020153414A5 (cg-RX-API-DMAC10.html)
JP2025502712A5 (cg-RX-API-DMAC10.html)